The Experts below are selected from a list of 273 Experts worldwide ranked by ideXlab platform
Mark Lebwohl - One of the best experts on this subject based on the ideXlab platform.
-
A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis
The New England Journal of Medicine, 2007Co-Authors: Gerald G. Krueger, Craig L Leonardi, Newman Yeilding, Lisa T Dooley, Richard G. Langley, Cynthia Guzzo, Yuhua Wang, Mark LebwohlAbstract:Background Skin-infiltrating lymphocytes expressing type 1 cytokines have been linked to the pathophysiology of psoriasis. We evaluated the safety and efficacy of a human interleukin-12/23 Monoclonal Antibody in treating psoriasis. Methods In this double-blind, placebo-controlled trial, 320 patients with moderate-to-severe plaque psoriasis underwent randomization to treatment with the interleukin-12/23 Monoclonal Antibody (one 45-mg dose, one 90-mg dose, four weekly 45-mg doses, or four weekly 90-mg doses) or placebo; 64 patients were randomly assigned to each group. Patients assigned to the interleukin-12/23 Monoclonal Antibody received one additional dose at week 16 if needed. Patients assigned to placebo crossed over to receive one 90-mg dose of interleukin-12/23 Monoclonal Antibody at week 20. Results There was at least 75% improvement in the psoriasis area-and-severity index at week 12 (the primary end point) in 52% of patients who received 45 mg of the interleukin-12/23 Monoclonal Antibody, in 59% o...
-
a human interleukin 12 23 Monoclonal Antibody for the treatment of psoriasis
The New England Journal of Medicine, 2007Co-Authors: Gerald G. Krueger, Craig L Leonardi, Newman Yeilding, Lisa T Dooley, Richard G. Langley, Cynthia Guzzo, Yuhua Wang, Mark LebwohlAbstract:Background Skin-infiltrating lymphocytes expressing type 1 cytokines have been linked to the pathophysiology of psoriasis. We evaluated the safety and efficacy of a human interleukin-12/23 Monoclonal Antibody in treating psoriasis. Methods In this double-blind, placebo-controlled trial, 320 patients with moderate-to-severe plaque psoriasis underwent randomization to treatment with the interleukin-12/23 Monoclonal Antibody (one 45-mg dose, one 90-mg dose, four weekly 45-mg doses, or four weekly 90-mg doses) or placebo; 64 patients were randomly assigned to each group. Patients assigned to the interleukin-12/23 Monoclonal Antibody received one additional dose at week 16 if needed. Patients assigned to placebo crossed over to receive one 90-mg dose of interleukin-12/23 Monoclonal Antibody at week 20. Results There was at least 75% improvement in the psoriasis area-and-severity index at week 12 (the primary end point) in 52% of patients who received 45 mg of the interleukin-12/23 Monoclonal Antibody, in 59% o...
Gerald G. Krueger - One of the best experts on this subject based on the ideXlab platform.
-
A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis
The New England Journal of Medicine, 2007Co-Authors: Gerald G. Krueger, Craig L Leonardi, Newman Yeilding, Lisa T Dooley, Richard G. Langley, Cynthia Guzzo, Yuhua Wang, Mark LebwohlAbstract:Background Skin-infiltrating lymphocytes expressing type 1 cytokines have been linked to the pathophysiology of psoriasis. We evaluated the safety and efficacy of a human interleukin-12/23 Monoclonal Antibody in treating psoriasis. Methods In this double-blind, placebo-controlled trial, 320 patients with moderate-to-severe plaque psoriasis underwent randomization to treatment with the interleukin-12/23 Monoclonal Antibody (one 45-mg dose, one 90-mg dose, four weekly 45-mg doses, or four weekly 90-mg doses) or placebo; 64 patients were randomly assigned to each group. Patients assigned to the interleukin-12/23 Monoclonal Antibody received one additional dose at week 16 if needed. Patients assigned to placebo crossed over to receive one 90-mg dose of interleukin-12/23 Monoclonal Antibody at week 20. Results There was at least 75% improvement in the psoriasis area-and-severity index at week 12 (the primary end point) in 52% of patients who received 45 mg of the interleukin-12/23 Monoclonal Antibody, in 59% o...
-
a human interleukin 12 23 Monoclonal Antibody for the treatment of psoriasis
The New England Journal of Medicine, 2007Co-Authors: Gerald G. Krueger, Craig L Leonardi, Newman Yeilding, Lisa T Dooley, Richard G. Langley, Cynthia Guzzo, Yuhua Wang, Mark LebwohlAbstract:Background Skin-infiltrating lymphocytes expressing type 1 cytokines have been linked to the pathophysiology of psoriasis. We evaluated the safety and efficacy of a human interleukin-12/23 Monoclonal Antibody in treating psoriasis. Methods In this double-blind, placebo-controlled trial, 320 patients with moderate-to-severe plaque psoriasis underwent randomization to treatment with the interleukin-12/23 Monoclonal Antibody (one 45-mg dose, one 90-mg dose, four weekly 45-mg doses, or four weekly 90-mg doses) or placebo; 64 patients were randomly assigned to each group. Patients assigned to the interleukin-12/23 Monoclonal Antibody received one additional dose at week 16 if needed. Patients assigned to placebo crossed over to receive one 90-mg dose of interleukin-12/23 Monoclonal Antibody at week 20. Results There was at least 75% improvement in the psoriasis area-and-severity index at week 12 (the primary end point) in 52% of patients who received 45 mg of the interleukin-12/23 Monoclonal Antibody, in 59% o...
Newman Yeilding - One of the best experts on this subject based on the ideXlab platform.
-
A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis
The New England Journal of Medicine, 2007Co-Authors: Gerald G. Krueger, Craig L Leonardi, Newman Yeilding, Lisa T Dooley, Richard G. Langley, Cynthia Guzzo, Yuhua Wang, Mark LebwohlAbstract:Background Skin-infiltrating lymphocytes expressing type 1 cytokines have been linked to the pathophysiology of psoriasis. We evaluated the safety and efficacy of a human interleukin-12/23 Monoclonal Antibody in treating psoriasis. Methods In this double-blind, placebo-controlled trial, 320 patients with moderate-to-severe plaque psoriasis underwent randomization to treatment with the interleukin-12/23 Monoclonal Antibody (one 45-mg dose, one 90-mg dose, four weekly 45-mg doses, or four weekly 90-mg doses) or placebo; 64 patients were randomly assigned to each group. Patients assigned to the interleukin-12/23 Monoclonal Antibody received one additional dose at week 16 if needed. Patients assigned to placebo crossed over to receive one 90-mg dose of interleukin-12/23 Monoclonal Antibody at week 20. Results There was at least 75% improvement in the psoriasis area-and-severity index at week 12 (the primary end point) in 52% of patients who received 45 mg of the interleukin-12/23 Monoclonal Antibody, in 59% o...
-
a human interleukin 12 23 Monoclonal Antibody for the treatment of psoriasis
The New England Journal of Medicine, 2007Co-Authors: Gerald G. Krueger, Craig L Leonardi, Newman Yeilding, Lisa T Dooley, Richard G. Langley, Cynthia Guzzo, Yuhua Wang, Mark LebwohlAbstract:Background Skin-infiltrating lymphocytes expressing type 1 cytokines have been linked to the pathophysiology of psoriasis. We evaluated the safety and efficacy of a human interleukin-12/23 Monoclonal Antibody in treating psoriasis. Methods In this double-blind, placebo-controlled trial, 320 patients with moderate-to-severe plaque psoriasis underwent randomization to treatment with the interleukin-12/23 Monoclonal Antibody (one 45-mg dose, one 90-mg dose, four weekly 45-mg doses, or four weekly 90-mg doses) or placebo; 64 patients were randomly assigned to each group. Patients assigned to the interleukin-12/23 Monoclonal Antibody received one additional dose at week 16 if needed. Patients assigned to placebo crossed over to receive one 90-mg dose of interleukin-12/23 Monoclonal Antibody at week 20. Results There was at least 75% improvement in the psoriasis area-and-severity index at week 12 (the primary end point) in 52% of patients who received 45 mg of the interleukin-12/23 Monoclonal Antibody, in 59% o...
Richard G. Langley - One of the best experts on this subject based on the ideXlab platform.
-
A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis
The New England Journal of Medicine, 2007Co-Authors: Gerald G. Krueger, Craig L Leonardi, Newman Yeilding, Lisa T Dooley, Richard G. Langley, Cynthia Guzzo, Yuhua Wang, Mark LebwohlAbstract:Background Skin-infiltrating lymphocytes expressing type 1 cytokines have been linked to the pathophysiology of psoriasis. We evaluated the safety and efficacy of a human interleukin-12/23 Monoclonal Antibody in treating psoriasis. Methods In this double-blind, placebo-controlled trial, 320 patients with moderate-to-severe plaque psoriasis underwent randomization to treatment with the interleukin-12/23 Monoclonal Antibody (one 45-mg dose, one 90-mg dose, four weekly 45-mg doses, or four weekly 90-mg doses) or placebo; 64 patients were randomly assigned to each group. Patients assigned to the interleukin-12/23 Monoclonal Antibody received one additional dose at week 16 if needed. Patients assigned to placebo crossed over to receive one 90-mg dose of interleukin-12/23 Monoclonal Antibody at week 20. Results There was at least 75% improvement in the psoriasis area-and-severity index at week 12 (the primary end point) in 52% of patients who received 45 mg of the interleukin-12/23 Monoclonal Antibody, in 59% o...
-
a human interleukin 12 23 Monoclonal Antibody for the treatment of psoriasis
The New England Journal of Medicine, 2007Co-Authors: Gerald G. Krueger, Craig L Leonardi, Newman Yeilding, Lisa T Dooley, Richard G. Langley, Cynthia Guzzo, Yuhua Wang, Mark LebwohlAbstract:Background Skin-infiltrating lymphocytes expressing type 1 cytokines have been linked to the pathophysiology of psoriasis. We evaluated the safety and efficacy of a human interleukin-12/23 Monoclonal Antibody in treating psoriasis. Methods In this double-blind, placebo-controlled trial, 320 patients with moderate-to-severe plaque psoriasis underwent randomization to treatment with the interleukin-12/23 Monoclonal Antibody (one 45-mg dose, one 90-mg dose, four weekly 45-mg doses, or four weekly 90-mg doses) or placebo; 64 patients were randomly assigned to each group. Patients assigned to the interleukin-12/23 Monoclonal Antibody received one additional dose at week 16 if needed. Patients assigned to placebo crossed over to receive one 90-mg dose of interleukin-12/23 Monoclonal Antibody at week 20. Results There was at least 75% improvement in the psoriasis area-and-severity index at week 12 (the primary end point) in 52% of patients who received 45 mg of the interleukin-12/23 Monoclonal Antibody, in 59% o...
Lisa T Dooley - One of the best experts on this subject based on the ideXlab platform.
-
A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis
The New England Journal of Medicine, 2007Co-Authors: Gerald G. Krueger, Craig L Leonardi, Newman Yeilding, Lisa T Dooley, Richard G. Langley, Cynthia Guzzo, Yuhua Wang, Mark LebwohlAbstract:Background Skin-infiltrating lymphocytes expressing type 1 cytokines have been linked to the pathophysiology of psoriasis. We evaluated the safety and efficacy of a human interleukin-12/23 Monoclonal Antibody in treating psoriasis. Methods In this double-blind, placebo-controlled trial, 320 patients with moderate-to-severe plaque psoriasis underwent randomization to treatment with the interleukin-12/23 Monoclonal Antibody (one 45-mg dose, one 90-mg dose, four weekly 45-mg doses, or four weekly 90-mg doses) or placebo; 64 patients were randomly assigned to each group. Patients assigned to the interleukin-12/23 Monoclonal Antibody received one additional dose at week 16 if needed. Patients assigned to placebo crossed over to receive one 90-mg dose of interleukin-12/23 Monoclonal Antibody at week 20. Results There was at least 75% improvement in the psoriasis area-and-severity index at week 12 (the primary end point) in 52% of patients who received 45 mg of the interleukin-12/23 Monoclonal Antibody, in 59% o...
-
a human interleukin 12 23 Monoclonal Antibody for the treatment of psoriasis
The New England Journal of Medicine, 2007Co-Authors: Gerald G. Krueger, Craig L Leonardi, Newman Yeilding, Lisa T Dooley, Richard G. Langley, Cynthia Guzzo, Yuhua Wang, Mark LebwohlAbstract:Background Skin-infiltrating lymphocytes expressing type 1 cytokines have been linked to the pathophysiology of psoriasis. We evaluated the safety and efficacy of a human interleukin-12/23 Monoclonal Antibody in treating psoriasis. Methods In this double-blind, placebo-controlled trial, 320 patients with moderate-to-severe plaque psoriasis underwent randomization to treatment with the interleukin-12/23 Monoclonal Antibody (one 45-mg dose, one 90-mg dose, four weekly 45-mg doses, or four weekly 90-mg doses) or placebo; 64 patients were randomly assigned to each group. Patients assigned to the interleukin-12/23 Monoclonal Antibody received one additional dose at week 16 if needed. Patients assigned to placebo crossed over to receive one 90-mg dose of interleukin-12/23 Monoclonal Antibody at week 20. Results There was at least 75% improvement in the psoriasis area-and-severity index at week 12 (the primary end point) in 52% of patients who received 45 mg of the interleukin-12/23 Monoclonal Antibody, in 59% o...
